866323-14-0

Basic information

• Product Name: PXD-101
• Synonyms: 2-PropenaMide, N-hydroxy-3-[3-[(phenylaMino)sulfonyl]phenyl]-, (2E)-;(2E)-N-Hydroxy-3-[3-[(phenylamino)sulfonyl]phenyl]-2-propenamide
• CAS NO: 866323-14-0
• Molecular Formula: C₁₅H₁₄N₂O₄S
• Molecular Weight: 318.34766
• Mol File: 866323-14-0.mol
• Article Data: 11

Chemical Properties

• Melting Point: 172 °C(Solv: ethyl acetate (141-78-6))
• Appearance: /
• Density: 1.427g/cm³
• Refractive Index: 1.667
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.27±0.10(Predicted)
• CAS DataBase Reference: PXD-101(CAS DataBase Reference)
• NIST Chemistry Reference: PXD-101(866323-14-0)
• EPA Substance Registry System: PXD-101(866323-14-0)

Safety Data

• Hazardous Substances Data: 866323-14-0(Hazardous Substances Data)

Usage

General Description

PXD-101, also known as Belinostat, is a potent inhibitor of histone deacetylases (HDAC), a group of enzymes involved in the regulation of gene expression. It exhibits antineoplastic activity, meaning it can prevent or inhibit the maturation and proliferation of malignant cells. PXD-101 works by interfering with the function of HDACs, leading to an accumulation of acetylated histones, which can result in chromatin remodeling, cell cycle arrest, differentiation, and apoptosis (programmed cell death). It is used in the treatment of various cancers, including peripheral T-cell lymphoma, and has been shown to enhance the efficacy of other anticancer agents.

InChI:InChI=1/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+

Upstream product

• 866323-87-7 (2E)-3-{3-[(phenylamino)sulfonyl]phenyl}prop-2-enoic acid 
• 610801-83-7 methyl (2E)-3-[3-(chlorosulfonyl)phenyl]prop-2-enoate 
• 866323-86-6 methyl (2E)-3-{3-[(phenylamino)sulfonyl]phenyl}prop-2-enoate 
• 405058-55-1 3-formyl-N-phenylbenzene-1-sulfonamide 
• 936-51-6 2-phenyl-1,3-dioxolane 
• 100-52-7 benzaldehyde 
• 4657-12-9 sodium hydroxy(phenyl)methanesulfonate 
• 53460-88-1 3-formylbenzenesulfonyl chloride 
• 62-53-3 aniline 
• 414864-00-9 N-hydroxy-3-(3-phenylaminosulfonylphenyl)acrylamide 
• 412269-00-2 C₁₅H₁₃NO₄S 
• 65-85-0 benzoic acid 
• 4025-64-3 3-Carboxybenzenesulfonyl chloride 
• 1576-45-0 3-[(phenylamino)sulfonyl]benzenecarboxylic acid 

Relevant articles and documents

POLYMORPHIC FORMS OF BELINOSTAT AND PROCESSES FOR PREPARATION THEREOF

The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.

NOVEL PROCESS FOR THE PREPARATION OF BELINOSTAT

The present invention provides a novel and commercially viable process with high yield for the preparation of (E)-N-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide, also known as Belinostat (I). The invention also provides process for purification and nov

The Development of an Effective Synthetic Route of Belinostat

A practical synthetic route of belinostat is reported. Belinostat was obtained via a five-step process starting from benzaldehyde and including addition reaction with sodium bisulfite, sulfochlorination with chlorosulfonic acid, sulfonamidation with aniline, Knoevenagel condensation, and the final amidation with hydroxylamine. Key to the strategy is the preparation of 3-formylbenzenesulfonyl chloride using an economical and practical protocol. The main advantages of the route include inexpensive starting materials and acceptable overall yield. The scale-up experiment was carried out to provide 169 g of belinostat with 99.6% purity in 33% total yield.